regend001

Cell therapyexperimental

Clinical trial activity

5 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started May 14, 2021 (NCT05657184)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06998706Phase 1Jun 30, 2025Jiao Tong University
NCT06987214Phase 1Jun 30, 2025Jiao Tong University
NCT06081621Phase 2Oct 20, 2023Chinese Academy of Medical Sciences, Jiao Tong University, Regend Therapeutics
NCT05638776Phase 2Jun 20, 2022Fudan University, Guangzhou Medical University, Huazhong University of Science and Technology, Jiao Tong University, Peking University, People's Liberation Army of China, Regend Therapeutics
NCT05657184Phase 1/Phase 2 (Phase 2)May 14, 2021Chinese Academy of Medical Sciences, Guangzhou Medical University, Jiao Tong University, Regend Therapeutics
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiao Tong UniversityAcademic/Hospital5222021
Regend TherapeuticsFor profit3312021
Chinese Academy of Medical SciencesAcademic/Hospital2012021
Guangzhou Medical UniversityAcademic/Hospital2012021
Fudan UniversityAcademic/Hospital1012022
Huazhong University of Science and TechnologyAcademic/Hospital1012022
Peking UniversityAcademic/Hospital1012022
People's Liberation Army of ChinaGovernment1012022
8 organizations
Page 1 / 1